Back to Archived News
Pivotal Patent Issued to VirtualScopics
Thursday, December 20, 2007
Patent Allows for a 95 Percent Reduction in Analysis Time With Improved Precision and Accuracy
Rochester, NY -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading developer of image-based biomarker solutions for the pharmaceutical, biotechnology and medical device industries, today announced it has received an important patent titled "Semi-Automated Measurement of Anatomical Structures Using Statistical and Morphological Priors," with Dr. Edward Ashton, Chief Scientific Officer at VirtualScopics, as the inventor.
Dr. Ashton stated, "The applications of the technology underlying this patent are extremely useful to our customers because they allow for more accurate and precise measurement of anatomical structures when compared to manual methods. This, coupled with a much quicker turnaround time due to a high degree of automation, provides our clients with a very cost effective and rapid turnaround of the critical information related to their drug development, which ultimately enables better decision making." He continued, "This approach has been tested and found to be effective for evaluation of muscle wasting, cardiovascular disease, and central nervous system diseases. It allows rapid and accurate measurement of a number of parameters, including muscle volume and cross-sectional area, arterial plaque volume and lumen diameter, and the volume of sub-structures of the brain such as the hippocampus."
The company is currently using the technology underlying this significant patent in many active clinical trials for its customers in the pharmaceutical, biotech, and medical device industries. This patent award is the seventh received by VirtualScopics for its proprietary image-based analytical tools.
About VirtualScopics, Inc.
VirtualScopics, Inc. is a provider of advanced medical image analysis services. The company evolved from research first carried out at the University of Rochester Medical Center and School of Engineering. VirtualScopics has created a suite of image analysis tools used in detecting and analyzing specific structures in volumetric medical images, as well as characterizing minute changes in structures over time, providing vital information to support clinical trials and diagnostic applications. The firm's proprietary software algorithms can assemble hundreds of separate medical images taken during an MRI session into a single, three-dimensional model, bringing a new and previously unobtainable source of data to clinical researchers. For more information about VirtualScopics, visit www.virtualscopics.com.
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.
Back to Archived News